Sequencing and Combining Idelalisib and Ibrutinib

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the prospect of sequencing or combining idelalisib and ibrutinib in lymphoid malignancies.

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the prospect of sequencing or combining idelalisib and ibrutinib in lymphoid malignancies.

Clinical Pearls:

  • Right now, there is no guidance on how to sequence the two agents
  • Ibrutinib should not be given to patients on anticoagulation agents, such as Coumadin
  • Side effect patterns will help physicians decide which agent a patient should receive